PRIMARY PERITONEAL CANCER
Clinical trials for PRIMARY PERITONEAL CANCER explained in plain language.
Never miss a new study
Get alerted when new PRIMARY PERITONEAL CANCER trials appear
Sign up with your email to follow new studies for PRIMARY PERITONEAL CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for Platinum-Resistant ovarian cancer: BL-M07D1 enters phase 3 trial
Disease control Not yet recruitingThis Phase 3 trial compares a new drug called BL-M07D1 against standard chemotherapy in 404 people with HER2-expressing ovarian, fallopian tube, or peritoneal cancer that has become resistant to platinum-based treatment. Participants will receive either BL-M07D1 or one of several…
Matched conditions: PRIMARY PERITONEAL CANCER
Phase: PHASE3 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New hope for ovarian cancer: Rina-S faces off against chemo in major trial
Disease control Not yet recruitingThis large Phase 3 trial will test a new drug called Rina-S, alone or with bevacizumab, against standard platinum-based chemotherapy for women with ovarian cancer that has returned after initial treatment. About 688 participants will be randomly assigned to receive either the new…
Matched conditions: PRIMARY PERITONEAL CANCER
Phase: PHASE3 • Sponsor: Genmab • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New hope for tough ovarian cancer: drug combo trial launches
Disease control Not yet recruitingThis study tests a combination of two drugs, liposomal irinotecan and enlonstobart, in 30 women with ovarian cancer that no longer responds to platinum chemotherapy. The goal is to see if the combo can shrink tumors and delay cancer growth. Participants receive treatment every tw…
Matched conditions: PRIMARY PERITONEAL CANCER
Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New drug senaparib tested in Real-World ovarian cancer study
Disease control Not yet recruitingThis study will observe 500 women with ovarian, fallopian tube, or primary peritoneal cancer who are taking the drug senaparib. Researchers will track side effects and how well the drug controls the cancer in real-world conditions, outside of a strict clinical trial. The goal is …
Matched conditions: PRIMARY PERITONEAL CANCER
Sponsor: Zhejiang Cancer Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New drug combo for BRCA ovarian cancer enters early testing
Disease control Not yet recruitingThis early-stage study tests two drugs, CKD-215 and D215, in 24 adults aged 19-75 with advanced BRCA-mutated ovarian, fallopian tube, or primary peritoneal cancer. The goal is to compare how the body processes each drug and check for side effects. Participants will receive both d…
Matched conditions: PRIMARY PERITONEAL CANCER
Phase: PHASE1 • Sponsor: Chong Kun Dang Pharmaceutical • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New triple therapy aims to stall return of ovarian cancer
Disease control Not yet recruitingThis study tests a combination of three drugs (Benmelstobart, Anlotinib, and low-dose Cyclophosphamide) in 40 women whose ovarian, fallopian tube, or peritoneal cancer has come back. The goal is to see if this mix can keep the cancer from growing for longer. Participants must be …
Matched conditions: PRIMARY PERITONEAL CANCER
Phase: PHASE2 • Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New combo therapy aims to shrink ovarian tumors before surgery
Disease control Not yet recruitingThis study tests whether adding an experimental immunotherapy (Aitua Combination Antibody) to standard chemotherapy can help shrink advanced ovarian cancer more effectively before surgery. About 82 women with stage IIIC-IV high-grade serous ovarian cancer who cannot have optimal …
Matched conditions: PRIMARY PERITONEAL CANCER
Phase: PHASE2 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New hope for ovarian cancer: drug combo targets relapsed patients
Disease control Not yet recruitingThis Phase 2 trial tests a new drug called JPI-547 combined with bevacizumab in 81 women with relapsed ovarian cancer who have already been treated with PARP inhibitors and responded to platinum chemotherapy. The study aims to find the best dose and see if the combination helps k…
Matched conditions: PRIMARY PERITONEAL CANCER
Phase: PHASE2 • Sponsor: Onconic Therapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New drug combo aims to shrink Hard-to-Operate ovarian tumors
Disease control Not yet recruitingThis study tests two drug combinations (fluzoparib plus famitinib or fluzoparib plus SHR-1701) given before surgery to shrink advanced ovarian cancer in 104 women whose tumors cannot be fully removed right away. The goal is to see how well these treatments work and how safe they …
Matched conditions: PRIMARY PERITONEAL CANCER
Phase: PHASE2 • Sponsor: Qinglei Gao • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Can a common supplement fight chemo brain? new trial aims to find out
Symptom relief Not yet recruitingThis study tests whether N-Acetyl-Cysteine (NAC), a supplement, can reduce chemotherapy-related cognitive impairment (often called 'chemo brain') in ovarian cancer patients. About 102 postmenopausal women with advanced ovarian cancer receiving platinum-based chemotherapy will tak…
Matched conditions: PRIMARY PERITONEAL CANCER
Phase: PHASE1, PHASE2 • Sponsor: University of California, Irvine • Aim: Symptom relief
Last updated Jun 27, 2026 12:25 UTC